Earnings summaries and quarterly performance for Mirum Pharmaceuticals.
Executive leadership at Mirum Pharmaceuticals.
Board of directors at Mirum Pharmaceuticals.
Research analysts who have asked questions during Mirum Pharmaceuticals earnings calls.
DL
David Lebowitz
Citigroup Inc.
4 questions for MIRM
Also covers: ALNY, ARWR, ASND +11 more
Gavin Clark-Gartner
Evercore ISI
4 questions for MIRM
Also covers: ACRS, ARGX, ASND +11 more
JF
Jessica Fye
JPMorgan Chase & Co.
4 questions for MIRM
Also covers: ALKS, ALNY, AMRN +23 more
Ryan Deschner
Raymond James Financial
4 questions for MIRM
Also covers: APLS, ARDX, ARSP +7 more
JW
Jon Wolleben
Citizen JMP
2 questions for MIRM
Also covers: BCRX, CLSD, MDGL +3 more
MU
Michael Ulz
Morgan Stanley
2 questions for MIRM
Also covers: ALNY, ARWR, FATE +8 more
Ryan Mcelroy
Leerink Partners
2 questions for MIRM
Also covers: BBIO, RGNX
Abdullah
J.P. Morgan
1 question for MIRM
Brian Skorney
Robert W. Baird & Co.
1 question for MIRM
Also covers: ABUS, CRNX, MRNS +6 more
Catherine Okoukoni
Citizens JMP
1 question for MIRM
Also covers: ALT, CRNX, KALV +2 more
DG
Dae Gon Ha
Stifel
1 question for MIRM
Also covers: ABEO, BEAM, CRBP +10 more
GC
Gavin Clark-Gardner
Evercore
1 question for MIRM
JW
Jonathan Wolleben
JMP Securities, a Citizens Company
1 question for MIRM
Also covers: ALT, BCRX, CLSD +5 more
Joseph Thome
TD Cowen
1 question for MIRM
Also covers: ALKS, AMLX, ARDX +12 more
JS
Josh Schimmer
Cantor Fitzgerald
1 question for MIRM
Also covers: BBIO, BYSI, CRNX +3 more
JS
Joshua Schimmer
Evercore ISI
1 question for MIRM
Also covers: KRYS, NBIX, SPRY
M
Mark
Stifel
1 question for MIRM
R
Rohit
Morgan Stanley
1 question for MIRM
Rohit Bhasin
Morgan Stanley
1 question for MIRM
Also covers: GUTS, VKTX
R
Ryan
B. Riley
1 question for MIRM
Also covers: BEEM, PATH, PPG
Selena Zhang
Morgan Stanley
1 question for MIRM
SR
Swayampakula Ramakanth
H.C. Wainwright & Co.
1 question for MIRM
Also covers: ABSI, BSEM, CGEN +24 more
TY
Thomas Yip
H.C. Wainwright & Co.
1 question for MIRM
Also covers: ABUS, ARDX, ENTA +6 more
Timur Ivannikov
Raymond James
1 question for MIRM
Also covers: APLS, GLMD, IFRX
Recent press releases and 8-K filings for MIRM.
Mirum Pharmaceuticals announces Health Canada approval for LIVMARLI® tablets and new indication
MIRM
Product Launch
- Health Canada has approved Mirum Pharmaceuticals' LIVMARLI® (maralixibat) tablets for the treatment of cholestatic pruritus in patients with Alagille syndrome.
- This new tablet formulation provides an additional option to the already approved oral solution in Canada, specifically for patients weighing at least 22 kg who are able to swallow tablets.
- Mirum Pharmaceuticals also announced that Health Canada has approved LIVMARLI® (both oral solution and tablets) for the treatment of cholestatic pruritus in patients aged 12 months or older with Progressive Familial Intrahepatic Cholestasis (PFIC).
2 days ago
Mirum Pharmaceuticals Announces Health Canada Authorization for LIVMARLI Tablet Formulation
MIRM
Product Launch
- Mirum Pharmaceuticals announced on February 5, 2026, that Health Canada has authorized the tablet formulation of LIVMARLI® (maralixibat) for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS).
- This new tablet formulation complements the existing 9.5 mg/ml oral solution, providing an additional dosing option for ALGS patients weighing 22 kg or more who are able to swallow tablets, enhancing dosing flexibility and continuity of care.
- LIVMARLI was previously authorized in Canada as an oral solution for the treatment of cholestatic pruritus in ALGS patients aged 12 months or older.
- On the same day, Mirum also announced Health Canada's authorization of LIVMARLI® for the treatment of cholestatic pruritus in patients aged 12 months and older with progressive familial intrahepatic cholestasis (PFIC), including both the 19 mg/mL oral solution and tablet formulations.
2 days ago
Mirum Pharmaceuticals Receives Health Canada Authorization for LIVMARLI in PFIC
MIRM
Product Launch
New Projects/Investments
- Mirum Pharmaceuticals announced that Health Canada has authorized LIVMARLI® (maralixibat) for the treatment of cholestatic pruritus in patients aged 12 months or older with progressive familial intrahepatic cholestasis (PFIC).
- The authorization includes both oral solution and tablet formulations, offering flexible dosing options for patients.
- This approval is supported by data from the Phase 3 MARCH study, which demonstrated a highly statistically significant reduction in pruritus severity in patients with PFIC.
2 days ago
Mirum Pharmaceuticals Completes Acquisition of Bluejay Therapeutics
MIRM
M&A
New Projects/Investments
Product Launch
- Mirum Pharmaceuticals, Inc. completed the acquisition of Bluejay Therapeutics on January 23, 2026.
- The acquisition grants Mirum worldwide rights to brelovitug, a late-stage monoclonal antibody for chronic hepatitis delta virus (HDV), which has received FDA Breakthrough Therapy and European Medicines Agency PRIME designations.
- Topline Phase 3 results for brelovitug are anticipated in the second half of 2026, with a potential Biologics License Application (BLA) submission and launch in 2027.
- The transaction included upfront consideration of up to $280.8 million in cash and 4,673,597 shares of common stock, along with potential milestone payments of up to $200 million in cash.
- Concurrently, Mirum completed private placement financings, raising approximately $268.5 million in gross proceeds to support clinical development and commercial activities for brelovitug.
Jan 26, 2026, 9:10 PM
Mirum Pharmaceuticals Completes Acquisition of Bluejay Therapeutics
MIRM
M&A
New Projects/Investments
- Mirum Pharmaceuticals has successfully completed its acquisition of Bluejay Therapeutics, expanding its global leadership in rare disease.
- The acquisition adds brelovitug to Mirum's portfolio, a late-stage, fully human monoclonal antibody for chronic hepatitis delta virus (HDV), which has received Breakthrough Therapy and PRIME designations.
- Topline Phase 3 results for brelovitug are expected in 2H 2026, with a potential BLA submission and launch in 2027.
- Concurrently, Mirum completed private placement financings, raising approximately $268.5 million in gross proceeds to support brelovitug's clinical development and commercial activities.
Jan 26, 2026, 1:00 PM
Mirum Pharmaceuticals Provides 2026 Guidance and Pipeline Updates at J.P. Morgan Healthcare Conference
MIRM
Guidance Update
New Projects/Investments
M&A
- Mirum Pharmaceuticals reported estimated $520 million in total product revenue for 2025 and issued 2026 guidance of $630-$650 million.
- The company anticipates several key pipeline readouts, including top-line data for the Volixibat VISTAS PSC study in Q2 2026, an interim look at the Brilovatug AZURE 1 program in Q2 2026, and top-line data for the Livmarli EXPAND study in Q4 2026.
- Mirum is progressing with the proposed acquisition of BlueJ Therapeutics, which will add Brilovatug for hepatitis delta, projected to be at least a $750 million opportunity, to its portfolio.
- Livmarli generated $359 million in net product revenue in 2025, with its tablet formulation having IP protection until 2043.
Jan 14, 2026, 7:15 PM
Mirum Pharmaceuticals Reports Strong 2025 Revenue and Provides 2026 Guidance, Highlights Pipeline Catalysts and BlueJay Acquisition
MIRM
Guidance Update
Revenue Acceleration/Inflection
M&A
- Mirum Pharmaceuticals reported an estimated $520 million in total product revenue for 2025 and issued 2026 guidance for total product revenue between $630 million and $650 million.
- The company expects several significant pipeline readouts in 2026, including top-line data for the Volixibat VISTAS PSC study and an interim look at the Brilovatug AZURE 1 program in Q2 2026, followed by top-line data for Brilovatug AZURE 1 and 4 in H2 2026, and the Livmarli EXPAND study in Q4 2026.
- Mirum announced the proposed acquisition of BlueJay Therapeutics, adding Brilovatug for hepatitis delta (HDV) to its portfolio, which is projected to be at least a $750 million opportunity.
- Livmarli, the company's lead product, achieved $359 million in net product revenue in 2025 and has a billion-plus potential opportunity, with average net pricing for Alagille syndrome patients ranging from mid-$400,000 to $500,000 per year.
Jan 14, 2026, 7:15 PM
Mirum Reports Strong 2025 Revenue, Issues 2026 Guidance, and Highlights Key Pipeline Catalysts
MIRM
Guidance Update
M&A
Revenue Acceleration/Inflection
- Mirum announced estimated $520 million in total product revenue for 2025 and provided 2026 guidance of $630-$650 million.
- The company anticipates several key pipeline readouts in the next 18 months, including Volixibat VISTAS PSC study top-line data in Q2 2026, Brilovatug AZURE programs top-line data in H2 2026, and Livmarli EXPAND study data in Q4 2026.
- Mirum is in the process of acquiring BlueJ Therapeutics, adding Brilovatug for hepatitis delta to its portfolio, which is seen as at least a $750 million opportunity.
- The company expects to be cash flow positive in 2027 and projects over $4 billion of potential revenue across its current commercial and pipeline programs.
Jan 14, 2026, 7:15 PM
Mirum Pharmaceuticals Announces Preliminary 2025 Results and 2026 Outlook
MIRM
Earnings
Guidance Update
M&A
- Mirum Pharmaceuticals reported preliminary unaudited 2025 net product sales of approximately $520 million, surpassing the upper end of its guidance, and projects 2026 global net product sales of $630 million to $650 million.
- The company achieved positive cash flow from operations in 2025 and ended the year with approximately $392 million in cash, cash equivalents, and investments as of December 31, 2025.
- Mirum is expanding its pipeline through the proposed acquisition of Bluejay Therapeutics, which will add brelovitug for chronic hepatitis delta virus (HDV), with topline Phase 3 data expected in H2 2026.
- Key clinical milestones anticipated for 2026 include topline data from the Volixibat VISTAS study in primary sclerosing cholangitis (PSC) in Q2 2026 and topline data from the LIVMARLI EXPAND study in additional cholestatic pruritus settings in Q4 2026.
Jan 12, 2026, 1:40 PM
Mirum Pharmaceuticals Announces Preliminary Unaudited 2025 Results and 2026 Outlook
MIRM
Earnings
Guidance Update
M&A
- Mirum Pharmaceuticals reported preliminary unaudited net product sales of approximately $520 million for 2025, surpassing the upper end of its guidance, with LIVMARLI sales at approximately $359 million and CHOLBAM and CTEXLI sales at approximately $161 million.
- For 2026, the company anticipates global net product sales between $630 million and $650 million.
- Mirum achieved positive cash flow from operations in 2025 and ended the year with an estimated cash, cash equivalents, and investments balance of approximately $392 million as of December 31, 2025.
- The proposed acquisition of Bluejay Therapeutics is expected to close in mid-to-late January 2026, adding brelovitug for chronic hepatitis delta virus (HDV) with topline Phase 3 data expected in H2 2026. Additionally, Volixibat VISTAS study topline data is expected in Q2 2026 and LIVMARLI EXPAND study topline data in Q4 2026.
Jan 12, 2026, 1:30 PM
Quarterly earnings call transcripts for Mirum Pharmaceuticals.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more